Primary periodic paralysis associated with hyperkalemic and hypokalemic attacks and with hemolytic bilirubinemia.
D000086:Acetazolamide / Q000627:therapeutic use; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000450:Aldosterone / Q000378:metabolism / Q000652:urine; D001663:Bilirubin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D004562:Electrocardiography; D004576:Electromyography; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006932:Hyperbilirubinemia / Q000150:complications*; D006947:Hyperkalemia / Q000150:complications* / Q000188:drug therapy; D007008:Hypokalemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007866:Leg; D008297:Male; D008797:Metyrapone / Q000627:therapeutic use; D010245:Paralyses, Familial Periodic / Q000209:etiology*; D010388:Pelvis; D011188:Potassium / Q000097:blood / Q000378:metabolism / Q000652:urine; D012964:Sodium / Q000097:blood / Q000378:metabolism / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use
D013148:Spironolactone; D000450:Aldosterone; D005665:Furosemide; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D012964:Sodium; D000086:Acetazolamide; D001663:Bilirubin; D011188:Potassium; D008797:Metyrapone